Package Insert: Information for the User
Calmatel18 mg/gGel
Read this package insert carefully before starting to use this medication, as it contains important information for you.
Follow exactly the administration instructions for the medication contained in this package insert or those indicated by your doctor, pharmacist, or nurse.
Calmatel contains piketoprofen and belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
This medicine is indicated for adolescents over 12 years old and adults for the local relief of mild and occasional pain and inflammation caused by:
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to use Calmatel.
This medication should be used exclusively on the affected area. It should not be used on large areas.
Apply the gel with caution on the skin, avoiding contact with eyes, mucous membranes, open ulcers or wounds, or other skin conditions.
It is recommended to avoid exposure to the sun and/or UVA rays during treatment with piketoprofeno and for up to two weeks after the last application.
It is recommended to wash your hands after applying the medication.
It is not recommended to use it with products that contain octocrylene (an excipient used in various cosmetic and hygiene products, e.g. sunscreens, shampoos, etc.), as they may cause skin reactions.
In case of skin reactions, you should immediately stop treatment and consult your doctor.
Frequent applications may cause skin irritation and dryness.
Due to its ethanol content, do not bring the gel tube close to open flames or direct fire, in case of a possible accident.
Children
This medication is not recommended for use in children (under 12 years old).
Use of Calmatel with other medications
Inform your doctor or pharmacist that you are using, have used recently, or may need to use any other medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
The use of medications during pregnancy may be hazardous to the embryo or fetus and should be monitored by your doctor.
The safety of piketoprofeno in breastfeeding women is unknown. Your doctor will advise you on whether it is safe to use this medication during breastfeeding.
Driving and operating machinery
Due to its administration form,this medication does not affect driving or operating machinery.
Calmatel containspropylene glycol.This medication contains 170 mg/g of propylene glycol.
Propylene glycol may cause skin irritation.
Follow exactly the medication administration instructions contained in this leaflet or those indicated by your doctor, pharmacist, or nurse. In case of doubt, ask your doctor, pharmacist, or nurse.
Dosage
Adolescents over 12 years and adults:
As a general rule, it will be applied to the affected area, approximately 1.5 to 2 g of gel, 3 times a day.
Administration form
For exclusive cutaneous administration.
Calmatel will be applied accompanied by a gentle massage to facilitate its penetration.You may feel a sensation of cold after the massage.
If symptoms do not improve in 7 days, discontinue treatment and consult a doctor.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, go to the nearest hospital, or contact the Toxicological Information Service, phone: 915 620 420 (indicating the medication and the amount used/ingested).
No cases of intoxication have been reported to date.
If you forgot to use Calmatel
Do not apply a double dose to compensate for the missed doses. Apply the missed dose when you remember and then continue with your regular schedule. However, if a few hours are left before the next application, do not apply the missed dose and wait for the next dose at the scheduled time.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, Calmatel may produce adverse effects, although not everyone will experience them.
Occasionally, reactions may occur at the application site, redness, itching, a burning sensation, and warmth at the application site, eczema, contact dermatitis, and photosensitivity reactions (increased sensitivity to sunlight).
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information about the safety of this medication.
Keep this medication out of the sight and reach of children.
No special storage conditions are required.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash.Deposit the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubtask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.
Composition of Calmatel
Appearance of the product and content of the container
Transparent, colorless or slightly yellowish gel with lavender odor, conditioned in a tin-coated aluminum tube; lacquered and printed on the outside; with a polyethylene screw cap.
Container of60 g.
Other presentations
Calmatel 18 mg/g Cream: Container of60 g.
Calmatel33.28 mg/mlSolution for cutaneous pulverization: Container of 60 ml, with propellant.
Holder of the marketing authorization and responsible for the manufacturing
Holderof the marketing authorization
Almirall, S.A.
General Mitre, 151
08022‑Barcelona (Spain)
Responsible for the manufacturing
Industrias Farmacéuticas Almirall, S.A.
Ctra. de Martorell, 41-6108740 Sant Andreu de la Barca Barcelona (Spain)
or
Almirall Hermal GmbH
Scholtzstraße 3
21465 Reinbek
Germany
Last review date of this prospectus: November 2013
The detailed and updated information of this medicine is available on the webpage of the Spanish Agency of Medicaments and Sanitary Products (AEMPS)http://www.aemps.gob.es/
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.